Company: PACB
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001299130-25-000090
Chunk: 107

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 107
---
) as a performance measure in any of our incentive programs. As a result, the impact of year-over-year fluctuations in our net income (loss) has less of an impact on compensation actually paid.

Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid (in millions) and Company-Selected Measure

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Company-Selected Measure during the five most recently completed fiscal years.

| 2025 Proxy Statement |     | 78 |

TABLE OF CONTENTS

#### Equity Compensation Plan Information
The following table presents information about the Company’s equity compensation plans as of December 31, 2024 (in thousands, except price data):

| Plan Category                                                 |     | Number of Securities 
 To Be Issued Upon    
 Exercise of          
 Outstanding Options, 
 Warrants and Rights  
 (a) (#)              |        |     |    |     | Weighted Average  
 Exercise Price of 
 Outstanding       
 Options, Warrants 
 and Rights ($)(1) |       |     | Number of Securities    
 Remaining Available For 
 Future Issuance Under   
 Equity Compensation     
 Plans (Excluding        
 Securities Reflected In 
 Column (a)) (#)         |        |
| Equity compensation plans approved by security holders(2)     |     |                      | 22,569 |     | -3 |     |                   |  8.30 |     |                         | 41,405 |
| Equity compensation plans not approved by security holders(4) |     |                      |  2,935 |     |    |     |                   | 24.43 |     |                         |  1,298 |
| Total equity compensation plans                               |     |                      | 25,505 |     |    |     |                   | 11.09 |     |                         | 42,703 |

(1) Represents the outstanding options’ weighted average exercise price and does not take into account the shares issuable upon vesting of outstanding PSUs or RSUs, which do not have an exercise price.

(2) Includes the following plans: the 2020 Plan, the 2010 Plan, the 2010 Director Plan and the 2010 Employee Stock Purchase Plan (“ESPP”). The 2020 Plan was approved by stockholders on August 4, 2020 and reserved 11,000,000 shares of the Company’s common